WASHINGTON (October 21, 2025) – Yesterday, AIDS Healthcare Foundation sent a letter signed by over 100 organizations to Gilead Sciences denouncing the company’s plan for high-single digit price hikes for several of its HIV medications. The immediate effect of the price spike guarantees that AIDS Drug Assistance Programs (ADAPs), a lifeline for low-income patients, will furnish fewer prescriptions to those most in need. Unfortunately, the decision to make life-saving therapeutics more expensive is not a one-off but follows a pattern under the leadership of Gilead’s CEO, Daniel O’Day.
O’Day has ruthlessly sought to boost profits by restricting access to Gilead’s HIV medicines. From patent manipulation to curtailing patient assistance programs, O’Day has proven that drug giants do not need to innovate to make money. Under his tenure, Gilead has put up multiple roadblocks to make it harder for medically underserved Americans to attain their medications. O’Day has had one goal – maximizing profits of the older drugs in Gilead’s portfolio instead of investing in the breakthrough HIV therapeutics of the future.
###
